Home / Market News / $GILD
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

UBS Adjusts Gilead Sciences Price Target to $195 From $175, Maintains Buy Rating

Oct 30, 2026, 3:03 PM UTC · Primary ticker $GILD

UBS has increased its price target for Gilead Sciences from $175 to $195 while reiterating a 'Buy' rating. This indicates a positive outlook from the analyst firm, potentially signaling increased investor confidence or improved financial prospects for Gilead Sciences.

UBS has adjusted its price target for Gilead Sciences upwards from $175 to $195, while simultaneously maintaining its 'Buy' rating on the stock. This action suggests that UBS analysts see increased value or improved future performance for Gilead Sciences, likely stemming from recent financial disclosures or market activities not detailed in this specific filing. For traders, this could be seen as a positive signal, potentially leading to short-term upward momentum for GILD shares as investors react to the analyst's upgraded outlook. In the long term, such analyst endorsements can contribute to sustained investor confidence, though the actual impact will depend on Gilead's fundamental performance and broader market conditions. A key opportunity for traders lies in anticipating the market's reaction to this positive analyst sentiment.

$GILD positive Price target increase and maintained Buy rating by UBS
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.